<DOC>
	<DOC>NCT02202226</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability and safety of Lu AF35700 after repeated oral dosing to patients with schizophrenia.</brief_summary>
	<brief_title>Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Men or women between 18 and 60 years (extremes included) BMI of ≤38 Primary diagnosis of schizophrenia according to DSMIVTR™ (codes 295.10, 295.20, 295.30, 295.90) Clinical Global Impression Severity of Illness (CGIS) score ≤4 (moderately ill) at screening and baseline PANSS total score ≤80 Score ≤4 (moderate) on the following PANSS items at screening and safety baseline: P7 (hostility), G8 (uncooperativeness) Willing to be hospitalised for 4 to 5 weeks after the Safety Baseline Visit The patient experienced an acute exacerbation requiring hospitalization within the last 6 months The patient experienced an acute exacerbation requiring change in antipsychotic medication (with reference to drug or dose) within the last 4 weeks The patient has a diagnosis or history of substance dependence (except nicotine) or substance abuse according to DSMIVTR® criteria ≤3 months prior to screening The patient smokes &gt;20 cigarettes per day Other protocoldefined inclusion and exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>